



The serum triglyceride to high-density lipoprotein cholesterol ratio predicts vascular events in patients with end-stage renal disease on hemodialysis

Jin Sug Kim, Da Rae Kim, Su Woong Jung, Yoo Ho Lee, Yang Gyun Kim, Ju Young Moon, Sang Ho Lee, Tae Won Lee, Chun-Gyoo Ihm, Kyung hwan Jeong

Division of Nephrology, Department of Internal Medicine, Kyung Hee University School of Medicine

BACKGROUND

- High triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio has been reported as an independent predictor for cardiovascular disease in the general population.
- However, the prognostic effect of the TG/HDL-C ratio on hemodialysis (HD) patients is unclear.
- We conducted this study with the aim of investigating whether TG/HDL-C ratio has a prognostic impact with regard to vascular events in HD patients.

METHODS

Study design and participants

- Single-center, prospective, observational cohort study,
- Between April 2012 to December 2015
- 189 patients with end-stage renal disease (ESRD) on HD were enrolled
- The TG/HDL-C ratio was categorized into tertiles based on the quantity of the study population and the distribution of TG/HDL-C ratio.

Study outcomes and Statistical analysis

- The outcomes were the occurrence of vascular events (cardiovascular [CV] events, arteriovenous fistula [AVF] failure, CV mortality, and all-cause mortality) during follow up periods.
- Cox proportional hazard regression analysis was evaluated for association of serum TG/HDL-C ratio with outcomes.

RESULT

- The patients consisted of 115 males and 74 females with age 60.5±13.2years.
- During a median of the 29.8-month follow-up period, 44(23.3%) patients experienced CV events and 63(33.3%) patients experienced AVF failure.
- 13(6.9%) deaths occurred, and 5 of which (38.5%) were caused by CV events.
- On multivariate Cox regression analysis, serum TG/HDL-C ratio was independently associated with increased risk of vascular events.

- The third tertile of the TG/HDL-C ratio (>2.97) was associated with increased risk of CV events (HR 3.31, CI 95% 1.31-8.38, p=0.01) and AVF failure (HR 2.28, CI 95% 1.15-4.52, p=0.02).
- The second tertile of the TG/HDL-C ratio (1.65-2.99) also showed increased risk of CV events (HR 2.89, CI 95% 1.12-7.48, p=0.03) and AVF failure (HR1.75, CI 0.86-3.57, p=0.12).
- From the Kaplan-Meier curves according to TG/HDL-C ratio, each tertiles showed a progressively worse event free survival and apparent separation (log-rank p =0.01 in CV events and p=0.02 in AVF failure).

Table 2. CV events, AVF failure, CV mortality, and all-cause mortality during follow-up

	TG/HDL-C ratio tertiles			P
	Tertiles 1	Tertiles 2	Tertiles 3	
CV events, n, (%)	6 (9.5%)	16 (25.4%)	20 (31.7%)	0.01
Stroke or TIA, n, (%)	0 (0%)	3 (5.9%)	3 (5.6%)	0.21
Acute coronary syndrome, n, (%)	6 (9.5%)	13 (19.5%)	17(26.1%)	0.04
AVF failure, n, (%)	13 (20.6%)	21 (33.3%)	27 (42.9%)	0.03
CV mortality, n, (%)	1 (1.6%)	2 (3.2%)	2 (3.2%)	0.81
All-cause mortality, n, (%)	5 (7.9%)	5 (7.9%)	3 (4.8%)	0.72

Table 3. Predictors of CV events in univariable and multivariable Cox regression analyses.

	Univariable		Multivariable	
	HR (95% CI)	p	HR (95% CI)	p
Age	1.03 (1.01-1.06)	0.02	1.02 (0.99-1.05)	0.27
Male sex	0.53 (0.29-0.97)	0.04	0.61 (0.26-1.44)	0.26
Dialysis vintage	1.01 (0.99-1.01)	0.11		
Hypertension	0.84 (0.39-1.81)	0.66		
Diabetes mellitus	1.73 (0.93-3.21)	0.08	0.85 (0.41-1.78)	0.66
Previous CVD	4.46 (2.34-8.49)	<0.001	3.88 (1.94-7.76)	<0.001
Body mass index	1.02 (0.95-1.10)	0.69		
Kt/V	2.31 (0.90-5.94)	0.08	1.49 (0.42-4.52)	0.60
CaxP	0.99 (0.96-1.01)	0.28		
Antihypertensive drugs	0.97 (0.49-1.96)	0.97		
Antiplatelet drugs	1.41 (0.73-2.76)	0.31		
Lipid lowering drugs	2.23 (1.22-4.09)	0.01	1.64 (0.84-3.22)	0.15
Tertile 2 vs.1	3.08 (1.21-7.88)	0.02	2.89 (1.12-7.48)	0.03
Tertile 3 vs. 1	3.80 (1.53-9.48)	<0.01	3.31 (1.31-8.38)	0.01

Table 4. Predictors of AVF failure in univariable and multivariable Cox regression analyses.

	Univariable		Multivariable	
	HR (95% CI)	p value	HR (95% CI)	p value
Age	1.01 (0.99-1.03)	0.21		
Male sex	1.28 (0.75-2.17)	0.36		
Dialysis vintage, month	1.00 (0.99-1.00)	0.36		
Hypertension	1.90 (0.82-4.42)	0.14		
Diabetes mellitus	1.62 (0.97-2.69)	0.06	1.27 (0.74-2.17)	0.38
Previous CVD	1.28 (0.76-2.15)	0.35		
Body mass index	0.96 (0.90-1.01)	0.12		
Kt/V	0.72 (0.33-1.58)	0.42		
CaxP	0.99 (0.96-1.00)	0.23		
Antihypertensive drugs	1.38 (0.73-2.59)	0.32		
Antiplatelet drugs	1.81 (1.02-3.20)	0.04	1.66 (0.93-2.96)	0.09
Lipid lowering drugs	1.09 (0.64-1.85)	0.74		
Tertile 2 vs.1	1.79 (0.89-3.59)	0.09	1.75 (0.86-3.57)	0.12
Tertile 3 vs. 1	2.49 (1.28-4.83)	0.01	2.28 (1.15-4.52)	0.02

CONCLUSION

- Our data suggest that a high serum TG/HDL-C ratio was associated with an increased risk of CV event and AVF failure in ESRD patients on HD, independently of several potential confounders. Further evaluations with large number are needed.

Table 1. Baseline characteristics of patients according to tertiles of TG/HDL-C ratio

	TG/HDL-C ratio tertiles			P
	Tertiles 1 (n=63) <1.65	Tertiles 2 (n=64) 1.65-2.96	Tertiles 3 (n=63) >2.97	
Age, y	60.7±13.4	59.9±14.3	60.9±11.9	0.406
Male, n, (%)	41 (65%)	34 (54%)	40 (64%)	0.385
Dialysis vintage, month	46.3±43.5	41.4±46.8	34.8±42.8	0.523
Hypertension, n, (%)	54 (86%)	51 (81%)	55 (87%)	0.589
Diabetes mellitus, n, (%)	22 (35%)	32 (51%)	37 (59%)	0.025
Previous CVD, n, (%)	20 (32%)	24 (38%)	23 (37%)	0.740
Body mass index, kg/m2	22.6±2.8	23.4±4.5	23.6±3.5	0.006
Laboratory data				
Hemoglobin, g/dL	9.9±0.9	10.3±1.1	10.1±1.1	0.196
Creatinine, mg/dL	9.7±2.9	9.3±3.1	8.6±2.9	0.814
Kt/V	1.5±0.3	1.5±0.3	1.4±0.4	0.487
K	4.9±0.7	4.8±0.7	4.7±0.8	0.903
CaxP	41.7±13.5	40.8±13.1	37.3±10.7	0.232
PTH	134.9±128.4	225.1±433.2	150.0±109.2	0.012
Albumin	3.8±0.2	3.9±0.3	3.9±0.3	0.774
Total cholesterol	145.7±31.3	146.1±35.2	143.2±30.5	0.486
Triglyceride	62.7±21.7	101.3±23.6	166.8±54.5	<0.001
HDL-C	57.7±12.7	44.3±9.0	36.1±7.5	0.001
LDL-C	76.9±24.3	85.9±29.7	83.6±28.0	0.391
TG/HDL-C	1.1±0.4	2.3±0.4	5.1±3.9	<0.001
Medications				
Antihypertensive drugs, n,(%)	50 (79%)	42 (67%)	50 (79%)	0.163
Antiplatelet drugs, n, (%)	40 (64%)	39 (62%)	40 (64%)	0.978
Lipid lowering drugs, n, (%)	14 (22%)	22 (35%)	26 (41%)	0.068